NantKwest

ImmunityBio gains $300 million in non-dilutive capital for commercialization and pipeline expansion efforts. ImmunityBio is developing immunotherapy products and cell therapies for cancer that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. ImmunityBio is working with the National Cancer Institute (NCI) on the largest Lynch syndrome cancer prevention study in the U.S. ImmunityBio’s platforms address the entire immune system, harnessing the power of both innate and adaptive functions of the immune system by activation of ‘first responder’ natural killer (NK) cells, T cells, and macrophages, and establishment of immune memory by dendritic cells. We are also leveraging our established neoepitope prediction pipeline to predict which unique tumor-associated neoepitope peptides have the potential to trigger an effective, anti-tumor immune response when delivered to patients as a personalized vaccine. We are applying our science and platforms, including the development of potential cancer vaccines, to treat cancers, as well as developing immuno- and cell therapies that we believe could sharply reduce or eliminate the need for standard high-dose chemotherapy. Our investigational immunotherapy products are tailored to each patient’s needs. We employ a “triangle” offense designed to deliver durable, complete responses in cancer and infectious diseases.